Thyroid carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The mRNA expression levels of CSC- (CD133 and CD44) and ES-related genes (Oct4 and Nanog) were higher in TC tissue than in normal thyroid tissue, whereas the mRNA expression levels of thyroid-specific genes (Tg, TSHR, and TTF1) were higher in normal thyroid tissue than in TC tissue.
|
30160089 |
2018 |
Thyroid carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemistry showed the positive expression of NIS and TSHR in thyroid cancer group.
|
30058701 |
2018 |
Thyroid carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Structural insight at atomic resolution of a TSHR antibody with inverse agonist activity opens the way for the development of a molecule with therapeutic potential, particularly in thyroid carcinoma.
|
29845889 |
2018 |
Thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
These studies evaluating the etiological roles of these factors in linking breast and thyroid cancer might also improve our understanding and identify new therapeutic approaches, such as sodium/iodide symporter-mediated radioiodine therapy and thyroid-stimulating hormone receptor antagonists, for breast cancer.
|
29976206 |
2018 |
Thyroid carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
This review examines the evidence for TSHR signaling as an oncogenic pathway and assesses the evidence for ongoing TSHR expression in thyroid cancer metastases.
|
28351942 |
2017 |
Thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Our meta-analysis suggests that TSHR-mRNA might be a potential biomarker to complete present diagnostic methods for early and precision diagnosis of thyroid cancer.
|
28036261 |
2017 |
Thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Here, we present an example of the construction of silicon dioxide nanoparticles with thyroid-stimulating-hormone receptor-targeting ligand that can specifically target the thyroid cancer.
|
28860762 |
2017 |
Thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
In addition, the prognostic value of TSHR in thyroid cancer was analyzed.
|
29344196 |
2017 |
Thyroid carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Different expression of TSH receptor and NIS genes in thyroid cancer: role of epigenetics.
|
24353283 |
2014 |
Thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The promoter region of TSHR gene was found to be methylated in 25 % (15 of 60) of the thyroid cancer patients.
|
24927793 |
2014 |
Thyroid carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
TSH receptor mRNA reverse transcription-polymerase chain reaction, the Veracyte and Asuragen commercial methods, and the noncommercial use of BRAF, RAS, RET/PTC, and PAX8/PPARγ testing have promising roles in the diagnosis and treatment of patients with nodular thyroid disease and thyroid cancer.
|
22984796 |
2013 |
Thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
In addition, there was no correlation between NIS and TSHR in thyroid cancer, which may explain why, even after TSH stimulation, 10-20% of these malignant tumors are unable to concentrate enough radioiodine for effective therapy.
|
21989446 |
2012 |
Thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Preoperative thyrotropin receptor messenger RNA was measured in 9 patients: 3 of 4 with thyroid cancer had elevated levels and 3 of 5 with goiters undetectable.
|
22244412 |
2012 |
Thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Mutations L677V and T620I identified in hot thyroid carcinomas were previously characterized in CHO and in 3T3-Vill cell lines, respectively, stably expressing the mutant without determination of TSHR expression.
|
20846293 |
2010 |
Thyroid carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
TSHR mRNA also represents a new blood test to aid assessment of disease status in thyroid cancer follow-up.
|
20881771 |
2010 |
Thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Recently, the value of thyroid-stimulating hormone receptor(TSHR) mRNA as a molecular marker in diagnosis of thyroid cancer has been greatly explored.
|
20429628 |
2010 |
Thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Gain-of-function mutations in the TSH receptor and the Galpha(S) subunit occur frequently in hyperfunctioning thyroid nodules and differentiated thyroid carcinomas, whereby the T allele of a common polymorphism (825C>T, rs5443) in the G protein beta3 subunit gene (GNB3) is associated with increased G protein-mediated signal transduction and a complex phenotype.
|
19772422 |
2009 |
Thyroid carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Circulating thyroid cancer cells detected by peripheral blood thyroid-stimulating hormone receptor (TSHR) mRNA have demonstrated usefulness for thyroid cancer diagnosis and long-term surveillance.
|
19958935 |
2009 |
Thyroid carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, monoclonal antibodies such as 5C9 may well provide the basis of new drugs to control TSHR activity including applications in thyroid cancer and Graves' ophthalmopathy.
|
18631002 |
2008 |
Thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
As such, this article addresses the following aspects of intragenic mutations in thyroid cancer: thyroid stimulating hormone receptor and guanine-nucleotide-binding proteins of the stimulatory family mutations in hyperfunctioning tumors; mutations in RAS and other genes and aneuploidy; PAX8-PPARgamma rearrangements; BRAF mutations; mutations in oxidative phosphorylation and Krebs cycle genes in Hürthle cell tumors; mutations in succinate dehydrogenase genes in medullary carcinoma and C-cell hyperplasia; and mutations in TP53 and other genes in poorly differentiated and anaplastic carcinomas.
|
18502330 |
2008 |
Thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
As disturbed thyrotropin receptor signaling plays a central role in hot thyroid nodules, the identification of effective low-molecular-weight thyrotropin receptor ligands, such as thyrotropin receptor agonists, inverse agonists and antagonists has a pharmacologic potential in the diagnosis and treatment of thyroid cancer, Graves' disease and hot thyroid nodules, respectively.
|
17940470 |
2007 |
Thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Methylation of thyroid-specific genes, such as those for sodium/iodide symporter and thyroid-stimulating hormone receptor, is also common in thyroid cancer.
|
16946009 |
2007 |
Thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Lastly, future investigation of epigenetic events occurring at the TSHR and other loci may give better clues for molecular based therapy of undifferentiated thyroid carcinomas.
|
17891229 |
2007 |
Thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Thyroid-stimulating hormone receptor messenger ribonucleic acid measurement in blood as a marker for circulating thyroid cancer cells and its role in the preoperative diagnosis of thyroid cancer.
|
17118994 |
2007 |
Thyroid carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Among these, thyroglobulin, and more recently thyroid-stimulating hormone receptor mRNAs' provide high diagnostic sensitivity and specificity for thyroid cancer detection.
|
17940468 |
2007 |